This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Bevespi Improves Lung Function in Phase III Study
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
by Zacks Equity Research
J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.
Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
by Zacks Equity Research
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
by Zacks Equity Research
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
by Zacks Equity Research
The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.
Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
by Zacks Equity Research
Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
by Zacks Equity Research
Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018
by Zacks Equity Research
Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018.
Key FDA Regulatory Events to Watch Out for in Sep 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?
Mylan and Otsuka Ink Agreement to Commercialize Deltyba
by Zacks Equity Research
Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.
Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have lost almost 19.4% in the year so far given the competitive pressure.
Are Glaxo's Successful New Drugs Enough to Drive Growth?
by Zacks Equity Research
Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
by Zacks Equity Research
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
Top Analyst Reports for Allergan, Ecolab & Exelon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Allergan (AGN), Ecolab (ECL) and Exelon (EXC).
Mylan Finalizes Settlement Agreement with DOJ for $465M
by Zacks Equity Research
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.
Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View
by Zacks Equity Research
Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.
Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.
GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
by Zacks Equity Research
Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.
Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK
by Zacks Equity Research
Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.